<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927039</url>
  </required_header>
  <id_info>
    <org_study_id>4-2021-0465</org_study_id>
    <nct_id>NCT04927039</nct_id>
  </id_info>
  <brief_title>Effects of Iloprost on Oxygenation During One-lung Ventilation in Supine-positioned Patients</brief_title>
  <official_title>Effects of Iloprost on Oxygenation During One-lung Ventilation in Supine-positioned Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One-lung ventilation (OLV) is essential during mediastinal mass excision. However, OLV&#xD;
      induces a drastic increase of intrapulmonary shunt due to maintained pulmonary perfusion&#xD;
      through the nonventilated lung. In addition, it is reported that supine positioning of&#xD;
      patient during OLV, which is required during mediastinal mass excision, results in worse&#xD;
      oxygenation than lateral decubitus positioning.&#xD;
&#xD;
      Iloprost is a prostaglandin analogue and when inhaled during OLV, it acts selectively on the&#xD;
      pulmonary vasculature, reducing pulmonary vascular resistance of well-ventilated lung and&#xD;
      thereby alleviating ventilation-perfusion mismatch. The purpose of this study is to evaluate&#xD;
      the effects of inhaled iloprost on oxygenation during one-lung ventilation in patients&#xD;
      undergoing mediastinal mass excision.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 24, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PaO2 (partial pressure of arterial oxygen) to FiO2 (fraction of inspired oxygen) ratio (P/F ratio)</measure>
    <time_frame>Twenty minutes after the completion of drug inhalation</time_frame>
    <description>The P/F ratio is a widely-used objective tool to identify hypoxemic respiratory failure when supplemental oxygen has been administered. It can be used to evaluate the effect of iloprost on oxygenation during OLV.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Mediastinal Mass</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Iloprost group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5ml of inhaled normal saline</intervention_name>
    <description>After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20μg (2ml) of inhaled iloprost (Ventavis®) and 3ml of inhaled normal saline</intervention_name>
    <description>After the initiation of OLV, mixture of iloprost 2ml and normal saline 3ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.</description>
    <arm_group_label>Iloprost group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients scheduled for Video-assisted thoracoscopic surgery (VATS) mediastinal mass&#xD;
             excision&#xD;
&#xD;
          2. Patient age from 20 to 80&#xD;
&#xD;
          3. American Society of Anaesthesiologists (ASA) physical status classification II~III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chronic obstructive pulmonary disease (COPD) with Forced expiratory volume in 1 second&#xD;
             (FEV1) to Forced vital capacity (FVC) ratio &lt; 0.7 and percentage of predicted FEV1 ≤&#xD;
             80%&#xD;
&#xD;
          2. Diffusing capacity of carbon monoxide (DLCO) &lt; 80%&#xD;
&#xD;
          3. Aspartate transaminase (AST) level ≥100 IU/mL or alanine transaminase (ALT) ≥ level 50&#xD;
             IU/L&#xD;
&#xD;
          4. Creatinine clearance ≤ 30mL/min&#xD;
&#xD;
          5. Congestive heart failure, arrhythmia&#xD;
&#xD;
          6. Unstable angina, coronary artery occlusive disease (CAOD), history of myocardial&#xD;
             infarction within 6 months&#xD;
&#xD;
          7. Pulmonary edema, pulmonary arterial hypertension&#xD;
&#xD;
          8. Allergic to prostaglandin or prostacyclin analogue&#xD;
&#xD;
          9. Patients with peptic ulcer bleeding, trauma, intracranial hemorrhage&#xD;
&#xD;
         10. History of cerebrovascular disease (e.g. transient ischemic attack, stroke) within 3&#xD;
             months&#xD;
&#xD;
         11. Valvular heart disease&#xD;
&#xD;
         12. Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyuho Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology and Pain Medicine, Severance Hospital, Yonsei University Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyuho Lee</last_name>
    <phone>82-2-2224-1636</phone>
    <email>theoneimlee@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Kyuho Lee</last_name>
      <phone>82-2-2224-1636</phone>
      <email>theoneimlee@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

